|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
DK2223922T3
(en)
|
2000-04-25 |
2016-06-06 |
Icos Corp |
Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
|
|
GB0119863D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
GB0119865D0
(en)
*
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
GB2405870B
(en)
*
|
2001-08-14 |
2005-07-06 |
Cancer Rec Tech Ltd |
DNA-PK inhibitors
|
|
TW589181B
(en)
*
|
2001-09-05 |
2004-06-01 |
Eisai Co Ltd |
Lymphocytic activation inhibitor and remedial agent for autoimmune disease
|
|
US7049313B2
(en)
|
2002-02-25 |
2006-05-23 |
Kudos Pharmaceuticals Ltd. |
ATM inhibitors
|
|
EP2311818B1
(en)
*
|
2002-02-28 |
2013-01-16 |
Novartis AG |
Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
|
|
AR038703A1
(es)
|
2002-02-28 |
2005-01-26 |
Novartis Ag |
Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
|
|
CN100430389C
(zh)
*
|
2002-08-16 |
2008-11-05 |
阿斯利康(瑞典)有限公司 |
抑制磷酸肌醇3-激酶β
|
|
JP4646626B2
(ja)
*
|
2002-08-16 |
2011-03-09 |
アストラゼネカ アクチボラグ |
ホスホイノシチド３−キナーゼβの阻害
|
|
KR101050700B1
(ko)
|
2002-08-26 |
2011-07-20 |
다케다 야쿠힌 고교 가부시키가이샤 |
칼슘 수용체 조절 화합물 및 이의 용도
|
|
JP2006510661A
(ja)
|
2002-12-06 |
2006-03-30 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
|
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
|
WO2004092154A1
(en)
*
|
2003-04-03 |
2004-10-28 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
JP2006523237A
(ja)
*
|
2003-04-03 |
2006-10-12 |
セマフォア ファーマシューティカルズ， インコーポレイテッド |
Ｐｉ−３キナーゼインヒビタープロドラッグ
|
|
MXPA05013210A
(es)
*
|
2003-06-05 |
2006-03-09 |
Warner Lambert Co |
Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
|
|
US20040259926A1
(en)
*
|
2003-06-05 |
2004-12-23 |
Bruendl Michelle M. |
3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
|
|
JP2006526608A
(ja)
*
|
2003-06-05 |
2006-11-24 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
|
|
BRPI0413467A
(pt)
|
2003-08-13 |
2006-10-17 |
Kudos Pharm Ltd |
aminopironas e seu uso como inibidoras da atm
|
|
BRPI0414171A
(pt)
*
|
2003-09-04 |
2006-10-31 |
Warner Lambert Co |
benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos
|
|
ATE365732T1
(de)
*
|
2003-10-31 |
2007-07-15 |
Warner Lambert Co |
Pyrimidine als inhibitoren von phosphoinositid-3- kinasen (pi3k)
|
|
WO2005095406A1
(en)
*
|
2004-01-26 |
2005-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
EP1761540B1
(en)
|
2004-05-13 |
2016-09-28 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
CN1300163C
(zh)
*
|
2004-06-23 |
2007-02-14 |
南京大学 |
3－羟基色原酮糖苷及其制法和用途
|
|
US7402607B2
(en)
|
2004-09-20 |
2008-07-22 |
Kudos Pharmaceuticals Limited |
DNA-PK inhibitors
|
|
JP2008529995A
(ja)
|
2005-02-09 |
2008-08-07 |
クドス ファーマシューティカルズ リミテッド |
Ａｔｍ阻害剤
|
|
AR053358A1
(es)
*
|
2005-04-15 |
2007-05-02 |
Cancer Rec Tech Ltd |
Inhibidores de adn - pk
|
|
WO2007127366A2
(en)
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
WO2007147217A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Prana Biotechnology Limited |
Method of treatment of glioma brain tumour
|
|
US8106071B2
(en)
*
|
2007-02-21 |
2012-01-31 |
Biobud Co., Ltd. |
Compositions for treating hyperproliferative vascular disorders and cancers
|
|
JP5672699B2
(ja)
|
2007-04-11 |
2015-02-18 |
味の素株式会社 |
血糖降下作用化合物のスクリーニング法
|
|
EP2154965A4
(en)
*
|
2007-05-29 |
2011-08-17 |
Glaxosmithkline Llc |
NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
|
|
US20100130597A1
(en)
*
|
2007-07-06 |
2010-05-27 |
The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service |
Dna-pkcs modulates energy regulation and brain function
|
|
RU2010133715A
(ru)
*
|
2008-01-25 |
2012-02-27 |
Астразенека Аб (Se) |
ЭНАНТИОМЕРНО ЧИСТАЯ (-)2-[1-(7-МЕТИЛ-2-(МОРФОЛИН-4-ИЛ)-4-ОКСО-4Н-ПИРИДО[1,2-a]ПИРИМИДИН-9-ИЛ)БЕНЗОЙНАЯ КИСЛОТА, ЕЕ ПРИМЕНЕНИЕ В ФАРМАКОТЕРАПИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
|
|
JP2011518174A
(ja)
*
|
2008-04-18 |
2011-06-23 |
シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体に関連する疾患を処置するための化合物及び方法
|
|
AU2009295948B2
(en)
|
2008-09-29 |
2013-12-05 |
GlaxoSmithKline, LLC |
Quinazolinone, quinolone and related analogs as sirtuin modulators
|
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
KR20160091440A
(ko)
|
2008-11-13 |
2016-08-02 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
NZ597579A
(en)
|
2009-07-02 |
2013-06-28 |
Sanofi Sa |
Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
|
|
ES2627428T3
(es)
|
2009-07-02 |
2017-07-28 |
Sanofi |
Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica
|
|
WO2011001115A1
(fr)
|
2009-07-02 |
2011-01-06 |
Sanofi-Aventis |
Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
|
|
MX2012000103A
(es)
|
2009-07-02 |
2012-05-22 |
Sanofi Sa |
Nuevos derivados de 1,2,3,4-tetrahidro-pirimido (1,2-a) pirimidin-6-ona, su preparacion y su uso farmaceutica.
|
|
AU2010276160A1
(en)
|
2009-07-21 |
2012-02-09 |
Gilead Calistoga Llc |
Treatment of liver disorders with PI3K inhibitors
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
IT1403156B1
(it)
*
|
2010-12-01 |
2013-10-04 |
Università Degli Studi Di Torino |
Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
|
|
FR2969613B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
|
|
FR2969612B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
|
|
US8815853B2
(en)
|
2010-12-23 |
2014-08-26 |
Sanofi |
Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
|
|
LT2658844T
(lt)
|
2010-12-28 |
2017-02-10 |
Sanofi |
Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
|
|
JP6000986B2
(ja)
*
|
2012-01-26 |
2016-10-05 |
第一三共株式会社 |
骨形成促進作用を有するクロモン誘導体
|
|
ES2697174T3
(es)
*
|
2012-02-10 |
2019-01-22 |
Ptc Therapeutics Inc |
Compuestos para tratar atrofia muscular espinal
|
|
KR102099997B1
(ko)
|
2012-03-01 |
2020-04-13 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
|
EA025407B1
(ru)
|
2012-03-05 |
2016-12-30 |
Джилид Калистога Ллс |
Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
|
|
US9914722B2
(en)
|
2012-03-23 |
2018-03-13 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
ITMI20120514A1
(it)
*
|
2012-03-29 |
2013-09-30 |
Cnr Consiglio Naz Delle Ric Erche |
Agente terapeutico per il trattamento dei vasi sanguigni
|
|
FR2992314B1
(fr)
|
2012-06-22 |
2015-10-16 |
Sanofi Sa |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
|
|
WO2015105657A1
(en)
|
2013-12-19 |
2015-07-16 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount of rna transcripts
|
|
NZ720867A
(en)
|
2013-12-20 |
2018-01-26 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
|
WO2015095605A1
(en)
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
|
JP6455995B2
(ja)
|
2014-06-13 |
2019-01-23 |
ギリアード サイエンシーズ， インコーポレイテッド |
ホスファチジルイノシトール３−キナーゼ阻害剤
|
|
JP6749343B2
(ja)
*
|
2015-05-20 |
2020-09-02 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
脊髄性筋萎縮症を処置するための化合物
|
|
US10668171B2
(en)
|
2015-05-30 |
2020-06-02 |
Ptc Therapeutics, Inc. |
Methods for modulating RNA splicing
|
|
KR20220100719A
(ko)
|
2015-12-10 |
2022-07-15 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료 또는 개선을 위한 조성물
|
|
ES2818531T3
(es)
|
2015-12-17 |
2021-04-13 |
Biokine Therapeutics Ltd |
Moléculas pequeñas para inhibir la actividad de las quimiocinas y/o el crecimiento de células cancerosas
|
|
EP3390378B1
(en)
|
2015-12-17 |
2022-03-30 |
AlonBio Ltd. |
Small molecules against cancer
|
|
CN109789144B
(zh)
*
|
2016-08-12 |
2022-04-15 |
马德拉医疗公司 |
蛋白激酶调节剂
|
|
CA3043755A1
(en)
|
2016-11-28 |
2018-05-31 |
Ptc Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
EP3573619A4
(en)
|
2017-01-27 |
2020-10-28 |
SignalRX Pharmaceuticals, Inc. |
THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
|
|
AU2018282154B2
(en)
|
2017-06-05 |
2022-04-07 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
KR20200017476A
(ko)
|
2017-06-14 |
2020-02-18 |
피티씨 테라퓨틱스, 인크. |
Rna 스플라이싱의 변경 방법
|
|
CA3067591A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
AU2019243048A1
(en)
|
2018-03-27 |
2020-10-15 |
Ptc Therapeutics, Inc. |
Compounds for treating Huntington's disease
|
|
BR112020026534A2
(pt)
|
2018-06-27 |
2021-03-23 |
Ptc Therapeutics, Inc. |
Compostos de heteroarila para o tratamento da doença de huntington
|
|
WO2020005882A1
(en)
|
2018-06-27 |
2020-01-02 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
IL279688B2
(en)
|
2018-06-27 |
2025-01-01 |
Ptc Therapeutics Inc |
Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
|
|
CN109748914B
(zh)
*
|
2018-12-29 |
2021-05-25 |
上海珂臻医药科技有限公司 |
吡啶并嘧啶类化合物及其应用
|
|
CN114245794B
(zh)
|
2019-05-13 |
2024-09-13 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的化合物
|
|
CN114096524B
(zh)
|
2019-05-15 |
2025-03-04 |
阿龙拜欧有限公司 |
用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子
|
|
AR121719A1
(es)
|
2020-04-03 |
2022-06-29 |
Petra Pharma Corp |
Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
|
|
CN111533721B
(zh)
*
|
2020-05-15 |
2022-04-26 |
浙江大学 |
苯并吡喃酮或喹啉酮类化合物及其应用
|
|
US20240208964A1
(en)
*
|
2020-06-03 |
2024-06-27 |
Pyridopyrimidines And Methods Of Their Use |
Pyridopyrimidines and methods of their use
|
|
EP4284375A4
(en)
*
|
2021-02-01 |
2025-04-23 |
Geode Therapeutics Inc. |
PHOSPHOINOSITIDE 3-KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREFOR
|
|
KR20240004865A
(ko)
|
2021-05-03 |
2024-01-11 |
페트라 파마 코포레이션 |
질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
|
|
EP4347040A1
(en)
|
2021-05-27 |
2024-04-10 |
Petra Pharma Corporation |
Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
|
|
TW202329930A
(zh)
|
2021-09-30 |
2023-08-01 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
|
|
CA3232906A1
(en)
*
|
2021-10-07 |
2023-04-13 |
Alessandro Boezio |
Pi3k-alpha inhibitors and methods of use thereof
|
|
WO2025136936A1
(en)
*
|
2023-12-19 |
2025-06-26 |
Merck Sharp & Dohme Llc |
Agonists of trem2 activity
|